MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, ABBV made $61,160M in revenue. $4,226M in net income. Net profit margin of 6.91%.

Income Overview

Revenue
$61,160M
Net Income
$4,226M
Net Profit Margin
6.91%
EPS
$2.36
Unit: Million (M) dollars
Revenue Breakdown
    • Immunology-SKYRIZI
    • Immunology-RINVOQ
    • HUMIRA-Immunology
    • Others
Revenue Breakdown
    • US
    • Other Countries
    • DE
    • Others

Income Statement
2025-12-31
2024-12-31
2023-12-31
2022-12-31
Net revenues
61,160 56,334 54,318 58,054
Cost of products sold
18,204 16,904 20,415 17,414
Selling, general and administrative
14,010 14,752 12,872 15,260
Research and development
9,096 12,791 7,675 6,510
Acquired ipr&d and milestones
5,016 2,757 778 697
Other operating income
241 7 179 -56
Total operating costs and expenses
46,085 47,197 41,561 39,937
Operating earnings
15,075 9,137 12,757 18,117
Interest expense, net
-2,627 -2,160 -1,684 -2,044
Net foreign exchange loss
-58 -21 -146 -148
Other expense, net
-5,793 -3,240 -4,677 -2,448
Earnings before income tax expense
6,597 3,716 6,250 13,477
Income tax expense (benefit)
2,364 -570 1,377 1,632
Net earnings
4,233 4,286 4,873 11,845
Net earnings attributable to noncontrolling interest
7 8 10 9
Net earnings attributable to abbvie inc
4,226 4,278 4,863 11,836
Basic EPS
2.37 2.4 2.73 6.65
Diluted EPS
2.36 2.39 2.72 6.63
Basic Average Shares
1,769,000,000 1,769,000,000 1,768,000,000 1,771,000,000
Diluted Average Shares
1,773,000,000 1,773,000,000 1,773,000,000 1,778,000,000
Unit: Million (M) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
US$15,202M (-64.67%↓ Y/Y)Non Us$2,360M US$5,940M (-86.20%↓ Y/Y)Non Us$2,364M US$3,062M (-92.88%↓ Y/Y)Non Us$1,478M US$3,151M (-92.68%↓ Y/Y)Non Us$618M US$3,612M (-91.61%↓ Y/Y)Non Us$9M US$2,048M (-95.24%↓ Y/Y)Collaboration revenues-Non Us$821M Non Us$1,486M US$1,306M (-96.96%↓ Y/Y)US$1,504M (-96.50%↓ Y/Y)Non Us$1,098M Non Us$682M US$635M (-98.52%↓ Y/Y)US$1,239M (-97.12%↓ Y/Y)Non Us$32M US$1,101M (-97.44%↓ Y/Y)Non Us$164M US$906M (-97.89%↓ Y/Y)Non Us$130M US$588M (-98.63%↓ Y/Y)Non Us$421M Non Us$608M US$385M (-99.11%↓ Y/Y)US$864M (-97.99%↓ Y/Y)Non Us$43M US$607M (-98.59%↓ Y/Y)Non Us$83M Non Us$369M US$124M (-99.71%↓ Y/Y)Non Us$315M US$167M (-99.61%↓ Y/Y)Non Us$221M US$189M (-99.56%↓ Y/Y)Non Us$308M US$73M (-99.83%↓ Y/Y)Collaboration revenues$181M Revenue From ContractWith Customer...$90M US$192M (-99.55%↓ Y/Y)Non Us$15M Non Us$144M US$53M (-99.88%↓ Y/Y)Immunology-SKYRIZI$17,562M Immunology-RINVOQ$8,304M HUMIRA-Immunology$4,540M BotoxTherapeutic-Neuroscience$3,769M Neuroscience-Vraylar$3,621M Imbruvica-Oncology$2,869M Oncology-VENCLEXTA$2,792M Other Products$2,627M Aesthetics-Botox Cosmetic$2,602M Creon-Other Key Products-US$1,512M MAVYRET-Other Key Products$1,317M Neuroscience-Ubrelvy$1,271M Aesthetics-Other Aesthetics$1,265M Neuroscience-Qulipta$1,036M Eye Care-Other EyeCare$1,009M Aesthetics-Juvederm Collection$993M LinzessConstella-Other Key Products$907M Elahere-Oncology$690M Eye Care-Ozurdex$493M Neuroscience-Vyalev$482M Eye Care-LumiganGanfort$410M Duodopa-Neuroscience$381M Epkinly-Oncology$271M Neuroscience-Other Neuroscience$207M Alphagan Combigan-EyeCare$197M Oncology-Other Oncology-US$33M Net revenues$61,160M (8.57%↑ Y/Y)Operating earnings$15,075M (64.99%↑ Y/Y)Total operating costsand expenses$46,085M (-2.36%↓ Y/Y)Other operatingincome$241M (3342.86%↑ Y/Y)Earnings before incometax expense$6,597M (77.53%↑ Y/Y)Other expense, net-$5,793M (-78.80%↓ Y/Y)Interest expense, net-$2,627M (-21.62%↓ Y/Y)Net foreignexchange loss-$58M (-176.19%↓ Y/Y)Cost of products sold$18,204M (7.69%↑ Y/Y)Selling, general andadministrative$14,010M (-5.03%↓ Y/Y)Research and development$9,096M (-28.89%↓ Y/Y)Acquired ipr&d andmilestones$5,016M (81.94%↑ Y/Y)Net earnings$4,233M (-1.24%↓ Y/Y)Income tax expense(benefit)$2,364M (514.74%↑ Y/Y)Net earningsattributable to abbvie inc$4,226M (-1.22%↓ Y/Y)Net earningsattributable to...$7M (-12.50%↓ Y/Y)

ABBV_BIG copy-svg

AbbVie Inc. (ABBV)

ABBV_BIG copy-svg

AbbVie Inc. (ABBV)